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Abstract
Gellan gum is a polysaccharide that has been recently proposed by our group for cartilage tissue-
engineering applications. It is commonly used in the food and pharmaceutical industry and has
the ability to form stable gels without the use of harsh reagents. Gellan gum can function as a
minimally invasive injectable system, gelling inside the body in situ under physiological conditions
and efficiently adapting to the defect site. In this work, gellan gum hydrogels were combined with
human articular chondrocytes (hACs) and were subcutaneously implanted in nude mice for 4 weeks.
The implants were collected for histological (haematoxylin and eosin and Alcian blue staining),
biochemical [dimethylmethylene blue (GAG) assay], molecular (real-time PCR analyses for collagen
types I, II and X, aggrecan) and immunological analyses (immunolocalization of collagen types I and
II). The results showed a homogeneous cell distribution and the typical round-shaped morphology
of the chondrocytes within the matrix upon implantation. Proteoglycans synthesis was detected by
Alcian blue staining and a statistically significant increase of proteoglycans content was measured
with the GAG assay quantified from 1 to 4 weeks of implantation. Real-time PCR analyses showed a
statistically significant upregulation of collagen type II and aggrecan levels in the same periods. The
immunological assays suggest deposition of collagen type II along with some collagen type I. The
overall data shows that gellan gum hydrogels adequately support the growth and ECM deposition
of human articular chondrocytes when implanted subcutaneously in nude mice. Copyright  2009
John Wiley & Sons, Ltd.
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1. Introduction
Cartilage is a supporting connective tissue, made up
broadly of proteins, polysaccharides and chondrocytes,
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that develops an important role in maintaining mobility
and a smooth gliding surface of joints in the skeleton.
This function is mainly assured by the extracellular
matrix that surrounds the chondrocytes, which is able
to withstand physical deformation and facilitate tissue
function. Chondrocytes synthesize and maintain this
extracellular matrix, producing especially collagen type II
and aggrecan, which confer articular cartilage its tensile
and compressive resistance, respectively. Cartilage has
a low metabolism that may constitute a serious barrier
to normal locomotion when the tissue is traumatized or
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degenerated. As healthy cartilage is only synthesized to
a short extent, and frequently this neocartilage presents
a much more pronounced fibrocartilaginous nature than
hyaline cartilage, pathological scenarios are triggered and
life quality is highly diminished (Temenoff and Mikos,
2000; Ge et al., 2006; Mano and Reis, 2007). Various
ways to address these problems have been suggested,
such as debridement or drilling, but the outcome is
still not satisfactory (Hunt et al., 2002; Jackson and
Dieterichs, 2003). Mosaicplasty (Hangody and Fules,
2003; Jakob et al., 2002), although being a widespread
surgical technique for treating a cartilage lesion, creates a
problem of reconstruction of the cartilage collection site
while repairing the original defect. Among the different
alternatives proposed was tissue engineering of cartilage
tissues (Freed et al., 1993; Vacanti and Vacanti, 1994;
Sittinger et al., 1994; Oliviera et al., 2006, 2008a), using
biomaterials, cells and/or bioactive agents. One of the
first definitions of tissue engineering was proposed by
Langer and Vacanti (1993). Since then, tissue-engineering
concepts have evolved and progressed through several
lines of study that range from nanotechnology-inspired
systems to rapid prototyping methods aimed at producing
hybrid structures (Capito et al., 2008; Moroni et al., 2006;
Hendriks et al., 2007; Tuzlakoglu et al., 2005; Andersson
and van den Berg, 2004). Also, the types of biodegradable
materials chosen passed from those already employed in
clinical procedures (in applications such as sutures, stents,
etc.) to others used in environmental applications (Videcki
et al., 2005) and the food industry (Mao et al., 2000).
Biomaterials used in regenerative medicine are frequently
divided in terms of their natural or synthetic origins.
Examples of the first include alginate (Rowley et al.,
1999), hyaluronic acid (Cortivo et al., 1991), chitosan
(Malafaya et al., 2008) and starch (Gomes et al., 2008),
and of the second, polyglycolic acid (Mooney et al.,
1996), polylactic acid (Cao et al., 1997) and polyethylene
oxide (Hubbell et al., 1991). Gellan gum is a biomaterial
of natural origin recently proposed for applications in
the cartilage regeneration field (Oliviera et al., 2008b,
2008c). It is a polysaccharide produced by bacterial
fermentation and its basic structural unit is composed of
glucose, rhamnose and glucuronic acid residues. Gellan
gum is able to form gels with differences in mechanical
properties, from soft and elastic to hard and brittle,
through an ionotropic gelation mechanism (Kang et al.,
1982; Grasdalen and Smidsrod, 1987). Other interesting
characteristics of the material include its heat and acid
resistance, gel formation under mild conditions without
using harsh reagents and its non-cytotoxic behaviour
(Oliviera et al., 2008d). Our group has suggested (Oliviera
et al., 2008c; 2008d) the use of gellan gum as an
encapsulating and support agent of different cells towards
the formation of a functional cartilaginous tissue. Human
articular cartilage chondrocytes were encapsulated and
cultured in vitro in optimized injectable gellan gum
systems for total periods of 8 weeks, maintaining their
viability and synthesizing hyaline-like extracellular matrix
components, mainly collagen type II and aggrecan.
In this work, gellan gum hydrogels were combined with
human articular chondrocytes acting as encapsulating
agents and supports for their development. Gellan gum
discs were formed and subcutaneously implanted in the
back of nude mice for 4 weeks periods. The in vivo results
showing the formation of a cartilage tissue of hyaline
nature suggest that these systems may be potentially used
in the repair of cartilage lesions.
2. Materials and methods
2.1. Human articular chondrocytes isolation
and expansion
Articular cartilage was harvested from the femoral head
and condyles macroscopically healthy parts of adult
patients (aged 40–65 years) undergoing replacement
surgery based on a protocol previously described by
Crawford and Dickenson (2004). This was performed
within the scope of a protocol established with the
Hospital de S. Marcos, Braga, Portugal, approved by
its Ethical Committee and always dependent upon the
patients’ informed consent. Human chondrocytes were
isolated by enzymatic digestion with posterior collection.
The human articular cartilage, freed from all surrounding
tissue, was placed in a Petri dish containing sterile
phosphate-buffered saline (PBS) and cut into square
slices of 5 mm2 and thickness 2–3 mm. The pieces
were washed in sterile PBS solution, immersed in 20 ml
trypsin–EDTA solution and incubated for 30 min at 37 ◦C
on a rotator. Trypsin was removed and the pieces
washed with basic DMEM (Sigma-Aldrich Co., USA).
Then, 20 ml filter-sterilized collagenase type II (Sigma-
Aldrich) solution (2 mg/ml) in basic medium was added,
and the mixture incubated for approximately 10 h at
37 ◦C on a rotator. The digested tissue and cell suspension
solution was centrifuged at 1200 rpm for 8 min and the
supernatant removed. The cell pellet was washed and
centrifuged twice with PBS and the cells counted using
a haemocytometer. Chondrocytes were then collected by
centrifugation and resuspended in expansion medium
consisting of Dulbecco’s modified Eagle’s medium (Sigma-
Aldrich) containing 10 mM HEPES buffer, pH 7.4,
1% antibiotic (antibiotic–antimycotic; Gibco 15 240),
20 mM L-alanyl glutamine, 1× MEM non-essential amino
acids and 10% v/v fetal bovine serum (FBS, heat-
inactivated; Biochrom, Berlin, Germany), supplemented
with 10 ng/ml basic fibroblast growth factor (bFGF;
PeproTech, UK). Human articular chondrocytes were
plated into tissue culture flasks and incubated at 37 ◦C in
a humidified atmosphere of 5% CO2 in air for expansion.
2.2. Human articular chondrocytes
encapsulation in gellan gum hydrogels
Human articular chondrocytes were expanded and
encapsulated at passage 2 in gellan gum hydrogels using
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the following procedure. Briefly, gellan gum powder
(G1910; Sigma-Aldrich) was mixed with sterile distilled
water under constant stirring at room temperature
to obtain a final concentration of 1.25% w/v. The
solution was progressively heated to 90 ◦C and kept at
this temperature for 20–30 min. The temperature was
progressively decreased to 42 ◦C and stabilized under
constant stirring. Human articular chondrocytes were
detached by trypsinization, mixed with culture medium
and centrifuged at 1200 rpm for 8 min. The supernatant
was removed and the cells were resuspended in sterile
PBS solution, counted using a haemocytometer and finally
centrifuged as before. The cell number was calculated
so that the final concentration after encapsulation was
5× 106 cells/ml. The supernatant was discarded and
the cells pellet kept at the bottom of the tube were
resuspended in PBS. The gellan gum 1.25% w/v solution
was extensively mixed with the chondrocytes suspension
for complete homogeneous dispersion within the gel.
Gellan gum with the encapsulated cells was allowed
to gel in a cylindrical mould for 2–3 min. Discs of
3 mm diameter ×3 mm height were cut using a sterile
blade and kept in sterile PBS before the implantation
procedure. Gellan gum discs with no cells encapsulated
were also prepared, using the same procedure, and used
as controls.
2.3. In vivo subcutaneous implantation in nude
mice
Six 4 week-old female Balb/C nude mice (Charles River
Laboratories Inc., USA), female with an average weight of
20 g, were anaesthetized with a mixture of ketamine
(1.2 mg/mouse s.c.; Imalgene 1000, Merial, Lyon,
France) and medetomidine (20 µg/mouse s.c.; Domitor,
Orion Corporation, Finland) prepared in physiological
serum. After the confirmation of analgesia/anaesthesia,
two incisions were made (reaching a maximum of 1.5 cm
each), one in the intrascapular region and another in
the lumbar region. With the help of forceps, two side
pockets were created through each of the incisions and
gellan gum discs with encapsulated chondrocytes and
with no encapsulated cells (control) were subcutaneously
implanted. Four discs were implanted per animal, two on
the anterior region and other two on the posterior region.
The incision sites were sutured and themice transferred to
heating recovery compartments and, when recovery from
analgesia/anaesthesia was confirmed, they were returned
to their respective compartments and kept under food
and drink ad libitum. After 1 week and 4 weeks post
implantation, the mice were euthanized (n = 3 for each
time point) by exposure to a saturated carbon dioxide
environment and the gellan gum discs were surgically
recovered and processed for histological, biochemical and
molecular analyses. The animal tests were performed
after analysis of the experimental plan and approval by
the Local Ethical Committee.
2.4. Histology
Common histological analysis was performed on 4 µm
thickness sections of the explants collected at different
periods of culture. Haematoxylin and eosin (H&E) stain-
ing was conducted to observe general cell morphology
and overall distribution, and Alcian blue was performed
to evaluate extracellular matrix components deposition,
viz. proteoglycans (glycosaminoglycans). Briefly, the con-
structs were carefully dissected from the subcutaneous
tissue of nude mice and collected in Eppendorf tubes.
They were immediately fixed in formalin for 30–40 min
and washed in PBS. Histological processing was con-
ducted by dehydrating the samples in increasing ethanol
concentrations, embedding them in paraffin and cutting
sections for posterior analysis using a Leica RM2155
microtome (Leica Microsystems, Nusslock GmbH, Ger-
many). H&E staining was performed using an automatic
processor according to in-house methodology (Leica
TP1020-1, Leica MicroSystems) and Alcian blue stain-
ing was performed using standard histological methods.
The slides were washed afterwards in distilled water,
dehydrated through increasing ethanol concentrations
and finally cleared in xylene substitute and mounted
using Microscopy Entellan (Merck & Co. Inc., USA) for
observation.
2.5. Quantification of proteoglycan content
Proteoglycans were determined by measuring the level
of sulphated glycosaminoglycans (GAGs), using 1,9-
dimethylmethylene blue (DMB) metachromatic assay,
as previously described by Kafienah and Sims (2004).
GAG levels can be quantified in solution using DMB,
since the mechanical entanglement of this reagent with
GAGs generates a peak shift at A525–530 that can be
measured spectrophotometrically. Briefly, the constructs
were carefully dissected from the subcutaneous tissue of
nude mice and collected in Eppendorf tubes. The samples
were ground with a mortar and pestle and immersed in
a digestion solution with papain and N-acetyl cysteine at
60 ◦C for approximately 3 h. The tubeswere centrifuged at
13 000 rpm for 10 min and the supernatant was collected
for biochemical analysis. A chondroitin sulphate standard
solution was prepared in water and kept at 4 ◦C. The
samples and the chondroitin sulphate standards were
placed in a 96-well round-bottomed plate, DMB solution
was added to each well, and the optical density was
measured using a microplate reader at 530 nm. Statistical
analyses were conducted using a two-sample t-test,
assuming unequal variances for n = 3.
2.6. Real-time PCR (collagen types I, II and X,
aggrecan)
The constructs were carefully collected upon dissection
of the subcutaneous tissue of nude mice, immersed
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in TRIzol (Invitrogen, USA) and quickly and stored
at −80 ◦C until the analysis was performed. RNA was
extracted using TRIzol and more details can be found
in the technical datasheet provided by the supplier.
Briefly, triplicates of each condition were ground and
mechanically homogenized with a mortar and pestle in
TRIzol. Chloroform was then added and the samples
centrifuged to establish a three-phase composition in
the tube, then the aqueous phase was collected to a
new tube and mixed with isopropanol. The samples
were again centrifuged, the supernatant discarded and
the pellet washed with 75% ethanol. The samples were
again centrifuged, allowed to dry in air and suspended
in ultrapure water for posterior analysis. The amounts
of isolated RNA and A260 : 280 ratio were determined
using Nanodrop ND-1000 Spectrophotometer (NanoDrop
Technologies Inc., USA). After these determinations,
RNA from each sample was reverse-transcribed into
cDNA, using the IScript cDNA synthesis kit (Bio-Rad
Laboratories, USA) in a BioRad CFX96 real-time PCR
detection system. Cartilage-related markers were chosen
to evaluate the chondrogenic phenotype of the cultured
systems. These included collagen types I, II and X
and aggrecan, using GAPDH as the housekeeping gene
for normalization. The expression of each gene was
normalized to the GAPDH value in that sample. The
relative gene expression quantification was performed
using the 2−!!Ct (Livak) method, considering that:
2−!!Ct = Normalized expression ratio
All the primer sequences were generated using Primer3
software (http://frodo.wi.mit.edu/) and acquired from
MWG Biotech, Germany. More details can be found
in Table 1. Real-time PCR was performed using a
BioRad CFX96 real-time PCR detection system and SYBR
Green IQ Supermix (Bio-Rad) to detect amplification
variations. The analyses of the results were performed
with CFX Manager Software, version 1.0 (Bio-Rad).
Statistical analyses were conducted using a two-sample
t-test, assuming unequal variances for n = 3.
2.7. Immunolocalization of collagen types I
and II
Collagen types I and II were detected immunohisto-
chemically, using monoclonal antibodies against collagen
types I and II (Southern Biotechnology, UK), using the
Vectastain Universal Elite ABC Kit PK-7200 (Vector
Laboratories Ltd, UK) and DAB Substrate Kit for Per-
oxidase SK-4100 (Vector Laboratories) according to the
suppliers’ instructions. Briefly, paraffin sections of the col-
lected explants were deparaffinized and hydrated through
decreasing ethanol concentrations. The sections were
treated with 3% hydrogen peroxide in 50% methanol for
5 min, washed in PBS buffer and incubated in prediluted
blocking serum. The incubation with the primary antibod-
ies and negative control followed (collagen type I, 1 : 100;
collagen type II, 1 : 20; normal horse serum, 1 : 100). The
remaining protocol is as described in the Vectastain Elite
ABC Kit. The sections were further incubated with the
DAB substrate at room temperature until suitable staining
develops, according to the supplier’s instructions. The sec-
tions were counterstained with neutral red, dehydrated
through increasing ethanol concentrations and finally
cleared in Xylene Substitute (National Diagnostics, USA)
and mounted using Microscopy Entellan (Merck, USA)
for observation.
3. Results
3.1. Histology
The explants collected after 1 and 4 weeks of implantation
were analysed using histological methods. H&E staining
was performed on the sections of the explants, since it
can provide relevant information on cell morphology and
distribution within the gel matrix. It was observed that the
cells had been homogeneously distributed throughout the
whole hydrogel, while also exhibiting the typical round-
shaped morphology of native articular chondrocytes.
An increase in cell mass was noticed after 4 weeks
of culture (Figure 1A), with individual chondrocytes
giving rise to clusters of two or three cells. Sulphated
glycosaminoglycans are important components of the
native articular cartilage extracellular matrix, due to
their water-retaining ability that highly contributes to
the mechanical functionality of the tissue. Sulphated
glycosaminoglycans were detected in histological sections
of the explants of the implanted gellan gum systems,
using Alcian blue staining, mostly after 4 weeks of
implantation (Figure 1B). The staining evolved from
a more orthochromatic nature in the early periods
to a pronounced metachromatic staining after 4 weeks
of implantation (Figure 1B). The positive staining was
localized in the pericellular regions of chondrocyte
clusters, its presence and intensity being quite regular
throughout the gellan gum matrix. It should also be
Table 1. Primers used for real-time PCR evaluation of human articular chondrocytes gene expression
Gene Accession No. Left primer Right primer
Collagen type I NM 000089 CTGCAAGAACAGCATTGCAT GGCGTGATGGCTTATTTGTT
Collagen type II NM 001844 TCACGTACACTGCCCTGAAG TGCAACGGATTGTGTTGTTT
Aggrecan NM 001135 ACAGCTGGGGACATTAGTGG GTGGAATGCAGAGGTGGTTT
Collagen type X NM 000493 AATCCCACAGGCATAAAAG AGGACTTCCGTAGCCTGGTT
GAPDH NM 002046 GAGTCAACGGATTTGGTCGT TTGATTTTGGAGGGATCTCG
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Figure 1. H&E (A) and Alcian blue (B) staining of histological sections of the explanted gellan gum hydrogels with human articular
chondrocytes after 4 weeks of culture. The cells divided in clusters of two or three cells and presented the typical round-shaped
morphology of native articular chondrocytes. Metachromatic staining, mostly in the pericellular regions, can be observed indicating
the deposition of extracellular matrix proteoglycans (glycosaminoglycans) (B)
mentioned that the discs maintained their structural
integrity upon microscopical observation and were well
integrated with the surrounding tissues.
3.2. Quantification of proteoglycan content
Following the qualitative analysis performed with Alcian
blue staining on histological sections of the gellan gum
hydrogels–human articular chondrocytes tissue explants,
the proteoglycan content of the constructs was quantita-
tively evaluated using the GAG assay. The glycosamino-
glycan content was found to increase steadily from 1
to 4 weeks of implantation, this variation being statisti-
cally significant (Figure 2). An increase of approximately
2.4-fold was measured in gellan gum tissue-engineered
constructs collected after 4 weeks compared with 1 week
of implantation. These results are in accordance with,
and reinforce the positive identification of, sulphated
glycosaminoglycans found in the histological analysis.
3.3. Real-time PCR (collagen types I, II and X,
aggrecan)
Real-time PCR was used to quantitatively assess the up-
and downregulation of genes typically associated with
chondrocytes and cartilage tissue formation (Figure 3).
Collagen types I, II, X and aggrecan are common
Figure 2. Graphical representation of the results obtained from
DMB assay for glycosaminoglycans (GAGs) quantification of the
explants after 1 and 4 weeks of implantation. A statistically
significant increase was observed from 1 to 4 weeks (p < 0.05)
ECM constituents present at different stages of the
chondrogenic process, and the transcription of their genes
was evaluated after 1 and 4 weeks of implantation. Among
those, collagen type II and aggrecan are considered to
be the two major and most important constituents of
hyaline cartilage ECM, since they are responsible for
the mechanical functionality of the tissue. Collagen type
I is associated with the dedifferentiation period that
frequently occurs in 2D culturing and is a reflection of
the poor hyaline nature of the tissue formed (Benya and
Shaffer, 1982; Cancedda et al., 1995). Collagen type X
is a marker associated with hypertrophic chondrocytes
and matrix mineralization, and its presence is a poor
indicator of the formation of a stable hyaline-like ECM
(von der Mark et al., 1992). The graphical representation
of the molecular analyses data shows a statistically
significant increase of both collagen type II and aggrecan
of approximately 230-fold and six-fold, respectively, from
1 to 4 weeks of implantation. Collagen type I and collagen
type X were not detected until the end of the experiments.
3.4. Immunolocalization of collagen types I
and II
As previously mentioned, collagen type II is the most
important major protein produced by chondrocytes
Figure 3. Real-time PCR analyses results for collagen type I,
collagen type II, aggrecan, and collagen type X during the
4 weeks of implantation. Collagen type II and aggrecan
presented statistically significant increases from 1 to 4 weeks,
indicating the hyaline-like nature of the newly formed tissue
(p < 0.05)
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Figure 4. Immunolocalization of collagen types I and II in histology sections of the explanted gellan gum hydrogels–human
articular chondrocytes systems after 4 weeks. Images show collagen type I, collagen type II and normal horse serum (negative
control) (left to right, respectively)
in articular cartilage, with key functions in the
weight-bearing ability and shock-absorbing properties of
the tissue. The analysis of the immunostaining profiles
(Figure 4) indicates that both collagen type I and type II
are present in the explants when compared with the neg-
ative control (normal horse serum). No striking difference
is encountered between collagen types I and II, although
some stronger staining may be noticed for type II. How-
ever, the qualitative evaluation is not simple, mostly due
to the background staining of the hydrogel that is also
present in the negative control. The identification of colla-
gen types I and II, with a suggested prevalence of the lat-
ter, is another evidence of the hyaline-nature ECM of the
tissue-engineered constructs and is in agreement with pre-
vious molecular data obtained from real-time PCR analy-
ses that showed an upregulation of collagen type II mRNA.
4. Discussion
Gellan gum hydrogels have been previously suggested
by our group (Oliviera et al., 2008b, 2008c, 2008d) for
applications in cartilage regeneration, since it possesses
adequate material properties for these purposes. It can be
used efficiently as a minimally invasive injectable system,
able to deliver and encapsulate cells and to support their
development in vitro. In those studies, human articular
chondrocytes were encapsulated in injectable gellan gum
hydrogels and cultured in vitro for extensive periods. The
chondrocytes were viable and formed a hyaline-like ECM
composed of collagen type II and aggrecan. The evaluation
of the in vivo response upon subcutaneous implantation
of these biomaterials was conducted in mice, revealing
good integration with the surrounding tissues and the
presence of a residual fibrotic capsule. The preliminary
data collected with these hydrogels was quite promising
regarding their potential use in the treatment of cartilage
pathologies, and further in vivo studies were set up to
validate this hypothesis, which are presented in this paper
(Oliveira et al., 2008d).32
In this study, gellan gum hydrogels were used to
encapsulate human articular chondrocytes and were
processed in the form of discs to be subcutaneously
implanted in the back of nude mice. The main
objective was to assess the formation of a hyaline-like
cartilage tissue and to conclude on the adequacy of
these systems to generate a functional tissue-engineered
construct with in vivo relevance in the future, using
histological, biochemical and molecular characterization
techniques. H&E staining of histological sections revealed
a homogeneous distribution of the chondrocytes within
the gellan gum matrix, with the cells exhibiting
the common round-shaped phenotype characteristic of
native chondrocytes. During the implantation time, the
chondrocytes exhibited active division (Figure 1B), which
is a good indication of their viability and growth
supported by the gellan gum hydrogels. Although these
are important aspects to take into account when following
cartilage tissue-engineering approaches, the essential
feature is the formation of a stable and functional tissue,
more precisely an ECM, that should be similar to the native
one. When referring to the mimetization of the native
articular cartilage ECM, efforts are frequently directed
to the creation of a matrix composed mostly of collagen
type II and aggrecan. In fact, these two molecules are
responsible for the important functions that cartilage has
in normalmobility and jointmovement. Articular cartilage
has a physical role in the tissue load-bearing properties,
mainly due to the interactions of water, ions and aggrecan
molecules within the collagenous meshwork. The collagen
type II confers tensile strength and the aggrecanmolecules
provide compressive stiffness to the tissue (Ge et al., 2006;
Knudson and Knudson, 2001). The study of the deposition
and quantification of proteoglycans, where aggrecan is
the most abundant, was performed with Alcian blue
staining and the GAG assay. The staining profile improved
from 1 to 4 weeks of implantation, mostly located in
the pericellular regions (Figure 1). The metachromatic
staining was more pronounced at the last time point,
indicating a higher deposition of proteoglycans by this
stage, thereby implying that the production of these
molecules increased during the course of the experiments.
These results are in accordance with the quantitative
analysis, which showed a statistically significant increase
from 1 to 4 weeks of implantation and reinforced the
fact that proteoglycans were being synthesized by the
encapsulated human articular chondrocytes. Real-time
PCR analyses were performed to quantify collagen types
I, II and X and aggrecan mRNA levels throughout the
time course of the experiments. A statistically significant
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upregulation of both collagen type II and aggrecan
mRNA levels was observed from 1 to 4 weeks of
implantation. As previously mentioned, these are the
most important components of the articular cartilage
ECM and the transcription of both genes emphasizes
that hyaline cartilage ECM is being deposited, opening
interesting prospects regarding future applications of this
biomaterial. To this can be added that collagen type
I and collagen type X are downregulated from 1 to
4 weeks. When in a two-dimensional (2D) environment
chondrocytes dedifferentiate, losing their round-shaped
phenotype and decreasing the production of collagen
type II and aggrecan, while increasing the production of
type I collagen (Cancedda et al., 1995; Vunjak-Novakovic
and Freed, 1998). The presence of collagen type I is
therefore a negative indicator for hyaline-like cartilage
ECM formation. Collagen type X is frequently expressed
by hypertrophic chondrocytes and is associated with
matrix mineralization. For instance, Kirsch et al. (1992)
observed that collagen type X synthesis is normally linked
to an increase of intracellular calcium and deposition of
calciummineral, ultimately leading tomatrix calcification.
Chondrocytes expressing this marker are usually part of
the deep zone of articular cartilage and its presence
indicates an hyperthrophic state of the chondrocytes,
which is not favourable when attempting to obtain an
articular cartilage-like ECM (Girkontaite et al., 1996).
The absence of both collagen type I and collagen type
X suggests that chondrocytes were able to redifferentiate
after the previous 2D expansion period in vitro but were
kept in that stage, since no collagen type X typical of
hyperthrophic chondrocytes could be detected. Finally,
to complement the analyses, immunological localization
of collagen type I and collagen type II was performed
on histological sections of the explants. Analysis of the
immunostained sections appears to indicate the presence
of stronger staining with the collagen type II antibody
when compared to collagen type I, which is in agreement
with the real-time PCR analyses, although the concluding
evidence of this is complicated by the background staining
of the hydrogel. Collagen type I expression is linked to the
dedifferentiation process that occurs in 2D culture and
the balance between collagen types I and II is frequently
used as an indicator of the cartilage type formed. The
presence of some collagen type I may relate to the
redifferentiation process, where collagen type I expression
starts to decrease and in turn collagen type II and aggrecan
are produced. The noticed stronger staining for collagen
type II suggests the deposition of a hyaline-like ECM by
the human articular chondrocytes encapsulated in gellan
gum hydrogels after implantation in the back of nude
mice.
Taken together, the results from this work have
shown that gellan gum hydrogels are adequate supports
for the growth and differentiation of human articular
chondrocytes when implanted subcutaneously in nude
mice, giving rise to the formation of a hyaline like
extracellular matrix. However, some aspects should be
considered when optimizing this system for further in vivo
applications. It is likely that the new cartilage tissue
formed would benefit from higher cell concentrations
and higher implantation periods in order to achieve
the formation of a tissue with improved potential. The
mechanical properties of these systems should also be
more thoroughly considered when approaching a load-
bearing in vivo scenario. However, the synthesis profiles of
collagen type II and aggrecan indicate that the mechanical
support that is lacking at an initial stage may in part be
assured by the newly formed ECM. Finally, it can be
referred that tests with alternative cell sources such as
stem cells should also be pursued. Given the scarcity of
cartilage samples with potential use in patients and the
immunological adversities that may arise from the use of
allogenous material, such an improvement might increase
the potential of gellan gum hydrogels as compared to
other systems proposed for these applications.
5. Conclusions
In this work, gellan gum hydrogels were used to encapsu-
late and support human chondrocyte development upon
in vivo subcutaneous implantation in nude mice. The
results were quite promising in terms of the generation
of a functional cartilage tissue-engineered construct. The
human chondrocytes proliferated during the 4 weeks of
the experiments and deposited a hyaline-like extracellular
matrix, typical of native articular cartilage. Collagen type
II and aggrecan showed increasing profiles, the results
being coherent in the analyses performed. The mainte-
nance of the hyaline cartilage phenotype was suggested
by the absence or decrease of collagen type I and colla-
gen type X. The in vivo performance of these systems so
far, along with previous data, suggests their further study
in larger animals and the testing of different parameters
towards the development of a fully functional cartilage
tissue-engineered construct to be applied clinically.
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